BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin YH, Wang H, Fiore A, Förster M, Tung LT, Belle JI, Robert F, Pelletier J, Langlais D, Nijnik A. Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma. J Cell Mol Med 2021;25:7089-94. [PMID: 34114734 DOI: 10.1111/jcmm.16554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Wang N, Huang X, Cheng J. Identification of the function, immunological role and m6A modification of MYSM1 in head and neck squamous cell carcinoma.. [DOI: 10.21203/rs.3.rs-1734482/v1] [Reference Citation Analysis]
2 Liang Y, Bhatt G, Tung LT, Wang H, Kim JE, Mousa M, Plackoska V, Illes K, Georges AA, Gros P, Henneman L, Huijbers IJ, Nagar B, Nijnik A. Deubiquitinase catalytic activity of MYSM1 is essential in vivo for hematopoiesis and immune cell development. Sci Rep 2023;13:338. [PMID: 36611064 DOI: 10.1038/s41598-023-27486-7] [Reference Citation Analysis]
3 Winkler R, Piskor EM, Kosan C. Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma. Cells 2022;12. [PMID: 36611833 DOI: 10.3390/cells12010037] [Reference Citation Analysis]
4 Zhang H, Liu S, Qin Q, Xu Z, Qu Y, Wang Y, Wang J, Du Z, Yuan S, Hong S, Chang Z, He W, Yan X, Lang Y, Tang R, Wang Y, Zhu L, Jiang X. Genetic and Pharmacological Inhibition of Astrocytic Mysm1 Alleviates Depressive-Like Disorders by Promoting ATP Production. Adv Sci (Weinh) 2022;10:e2204463. [PMID: 36414403 DOI: 10.1002/advs.202204463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lin YH, Wang H, Fiore A, Förster M, Tung LT, Belle JI, Robert F, Pelletier J, Langlais D, Nijnik A. Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma. J Cell Mol Med 2021;25:7089-94. [PMID: 34114734 DOI: 10.1111/jcmm.16554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]